ReviewDermatologie (Heidelberg, Germany)2025
[Relevant aspects of Candida species in dermatology : An overview].
Review in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Biologics and infections: treat and prevent].Dermatologie (Heidelberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida species are opportunistic yeasts that form part of the normal human microbiota. Under certain conditions, such as immunosuppression, alterations in the microbiota, or disruption of the skin barrier, these commensals may become pathogenic and lead to clinically relevant infection. Candida (C.) albicans plays a central role in skin and mucosal infections, while other species, such as Nakaseomyces (N.) glabratus (formerly known as Candida glabratus) and C. auris, are increasingly gaining clinical significance. The most common Candida infections affect the skin and mucosal membranes; however, under predisposing factors, the pathogen can enter the bloodstream, leading to septicemia with organ involvement. In this context, multidrug-resistant pathogens, particularly C. auris, pose an escalating threat to public health. Diagnosis of Candida species is generally performed using conventional microbiological techniques, including cultures and microscopy, as well as advanced molecular methods such as polymerase chain reaction (PCR) and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Given the rising rates of resistance and the associated therapeutic challenges, accurate species identification and resistance profiling prior to antifungal treatment are critical. Preventive measures, especially for high-risk populations, are crucial to reduce the incidence of Candida infections. While many superficial Candida infections can be managed with hygiene practices and topical antifungal treatments, invasive candidiasis necessitates close collaboration between microbiology, pharmacology, and infectious disease specialists to ensure optimal patient care.
Indexed as
Identifiers
40643642What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.